Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENCORE 602: Entinostat plus Atezolizumab in Advanced TNBC
NCT02708680Phase 2Completed
- Sponsor
- Syndax Pharmaceuticals
- Start
- May 2016
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of entinostat in triple-negative breast cancer (TNBC), sponsored by Syndax Pharmaceuticals. Started May 2016; status: completed.
02
Drugs
entinostat
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02708680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02708680.